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Editorial on the Research Topic
Medical and Industrial Applications of Microfluidic-based Cell/Tissue Culture and
Organs-on-a-Chip
Cell culture on Petri dish remains the gold standard in basic research for screening drug candidates
during one of the most expensive and lengthy industrial product development. However, the
artifactual environment and the oversimplified structure of this one-cell-type culture system do
not mimic the in vivo dynamic nature and heterogeneous architecture. Hence, it is not able to
answer increasingly emerging biological questions. Animal models, on the other hand, provide
systemic in vivo settings. However, despite the wealth of knowledge acquired from these models,
many details of human pathogenesis cannot be addressed because of the differences between animal
and human immune responses in preclinical studies vs. clinical trials (Mestas and Hughes, 2004;
Zschaler et al., 2014). Costs associated with the failure in predicting the toxicity and efficacy of
a drug candidate, particularly in the clinical trial stages, have become overwhelmingly expensive
(Mullard, 2018). Therefore, the pharmaceutical industry needs to develop more predictive tools
that reduce the chance of failure.
The past two decades have seen a rapid growth of microfluidics-based cell culture technology,
with the ultimate aim to boost the development of fundamental bioscience and pharmaceutics. The
versatile functionality and excellent spatiotemporal control over micro-environmental elements
in microfluidic-based cell culture open up wide possibilities for tissue engineering and next-
generation drug discovery. A remarkable development that is recently emerged is the ability to
co-culture various type of cells in an integrated fluidic network to emulate a specific human tissue or
organ simplified structure and function, called organs on a chip (OOC). A plethora of microfluidic-
based culture models have been developed; however, the adaptation of this technology to address
biological questions still scattered.
Here, we have assembled papers by contributors from prominent research labs that discuss
fundamental questions and highlight the recent development in this emerging and rapidly
advancing technology. There are five unique reviews, one perspective paper, and six original
research papers in this issue that present a critical assessment of recent literature and demonstrate
new advances in the field.
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Avendano et al. discuss the effect of the physical
microenvironment remodeling associated with cancer
progression on mass transport in the tumor interstitial
space. They examine the application and future opportunities
of microfluidic models to better identify the physiochemical
mediators of the mass transport. To maintain in vivo-like mass
transfer and cell-cell communication in vitro, heterotypic cell co-
culture is essential to mimic tissues and organs. Achieving such a
heterotypic structure requires controlling the cell adhesion with
desired patterns, Yaman et al. review the application of magnetic
force-based cell manipulation in microfluidic devices and the
potential use of this technique in guidance of cells into a specific
location and creating heterotypic cellular structures in 2D and
3D organization.
Three papers in this collection focus on the brain tissue.
In vitro modeling of the brain tissue, including the blood-brain
barrier, and related diseases requires a high level of biological and
fluidic design, as it is critical to replicate the complex network
of different brain regions. Frimat and Luttge emphasize the
advantages of combining engineered microsystems with stem
cell (hiPSC) technology to improve the performances of brain-
on-a-chip devices and their clinical relevance. Badiola-Mateos
et al. address the challenges of modeling the neuromuscular
circuit and recommend the combination of microfluidic systems,
hiPSC and 3D culture to create patient-specific and reliable
in vitro models. Qiao et al. discuss recent work on organoid-
on-a-chip (Wang et al., 2018) as an alternative human-
relevant neurodevelopmental model and its potential use
for understanding the effects of prenatal nicotine exposure
in the early stages of embryonic development, eliminating
ethical concerns regarding human clinical trials in smoking
pregnant women.
Spheroids and organoids have become popular tools for
oncology and for basic and translational patient-specific tissue
research. In order to grow large tissue models and organoids,
the cells within the artificial tissue need continuous feeding
through an in vivo-like capillary network. Mimicking the human
vasculature, which can be viewed as a complex closed-loop
perfusion system, represents one of the major in vitro challenges.
Grebenyuk and Ranga reviewed the recent progress in generating
in vitro vascularization. To date, nearly all fabrication techniques
fall short to keep cells in 3D tissues alive during the slow
fabrication process. Organ-on-a-Chip technology would enable
the incorporation of the right cells at the right place, ultimately
achieving perfusable organoids. An unconventional approach is
reported by Bottaro et al. to demonstrate physical vein models by
populating the surfaces of a PDMS mold with endothelial cells
to simulate blood vessels and characterize the fluidic behavior of
sclerosing foams.
Another significant challenge, especially when reconstructing
epithelial tissues in vitro, is to obtain a realistic barrier function
which is reviewed by Torras et al. Various epithelial barriers
have been demonstrated in vitro, including lungs, intestine and
skin. Bioprinting and photolithography are used for producing
engineered complex basement membrane, recapitulate the
properties of native epithelial tissues and provide robust
predictive models.
Besides providing physiologically relevant cellular structure
and fluidic environment, microfluidic devices also allow
simulating the micro- and macro-mechanical features in human
tissue. For instance, Felder et al. examined the effect of cyclic
mechanical stress induced by respiratory motions, which was
mimicked using a thin membrane, on alveolar wound repair.
Recent breakthroughs in microbiology and medical sciences
have highlighted the importance that the microbiota has on
human health. Shin et al. demonstrated an in vitro anoxic-
oxic interface of obligate anaerobic gut microbiome and human
intestinal epithelial cells co-culture in a microfluidic chip and
highlighted the importance of the host-microbiome crosstalk to
the homeostasis of gastrointestinal functions.
Among all in vitro models, liver models play a central role
in drug discovery. Accurate in vitro modeling of the liver is
challenging because different hepatic functions are specific to the
hepatocytes’ spatial location within a liver lobule, which translate
in different levels of gene expression and metabolic competence.
Supported by a mathematical model, Tomlinson et al. used a
Quasi Vivo system to create a zonated in vitro liver model
in which primary rat hepatocytes cultured in three chambers
are exposed to varying oxygen tension. This system provides a
more accurate evaluation of pharmacological interventions at a
zone-specific level.
Finally, in order to become widely accepted, these new culture
systems need to overcome several drawbacks, such as the ability
to control the concentrations of soluble factors, especially drugs.
Lohasz et al. takes advantage of a tubing-free microfluidic device
architecture to construct a microtissue culture system to generate
gradual in vivo-like substance exposure profiles. The device not
only eliminates the tedious interconnections for microfluidic
device but also provides a great capability to control compound
gradients in spatiotemporal domains.
This exciting collection of papers represent an excellent
fit into the “Frontiers in Bioengineering and Biotechnology”
with state-of-the-art contributions and critical reviews on the
new advances in this growing field, with an emphasis on the
interface between the technological advancements and high
impact applications. We are delighted to be a part of this
effort and witness the rapid expanding of the organ-on-a-chip
technology toward opening the door to a variety of scientific and
commercial avenues.
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